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Abstract
Objective
A number of promising experimental therapies for Duchenne muscular dystrophy (DMD)
are emerging. Clinical trials currently rely on invasive biopsies or motivation-dependent
functional tests to assess outcome. Quantitative muscle magnetic resonance imaging
(MRI) could offer a valuable alternative and permit inclusion of non-ambulant DMD sub-
jects. The aims of our study were to explore the responsiveness of upper-limb MRI mus-
cle-fat measurement as a non-invasive objective endpoint for clinical trials in non-
ambulant DMD, and to investigate the relationship of these MRI measures to those of mus-
cle force and function.
Methods
15 non-ambulant DMD boys (mean age 13.3 y) and 10 age-gender matched healthy con-
trols (mean age 14.6 y) were recruited. 3-Tesla MRI fat-water quantification was used to
measure forearm muscle fat transformation in non-ambulant DMD boys compared with
healthy controls. DMD boys were assessed at 4 time-points over 12 months, using 3-point
Dixon MRI to measure muscle fat-fraction (f.f.). Images from ten forearm muscles were
segmented and mean f.f. and cross-sectional area recorded. DMD subjects also underwent
comprehensive upper limb function and force evaluation.
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Results
Overall mean baseline forearm f.f. was higher in DMD than in healthy controls (p<0.001). A
progressive f.f. increase was observed in DMD over 12 months, reaching significance from
6 months (p<0.001, n = 7), accompanied by a significant loss in pinch strength at 6 months
(p<0.001, n = 9) and a loss of upper limb function and grip force observed over 12 months
(p<0.001, n = 8).
Conclusions
These results support the use of MRI muscle f.f. as a biomarker to monitor disease progres-
sion in the upper limb in non-ambulant DMD, with sensitivity adequate to detect group-level
change over time intervals practical for use in clinical trials. Clinical validity is supported by
the association of the progressive fat transformation of muscle with loss of muscle force
and function.
Introduction
DuchenneMuscular Dystrophy (DMD) is an X-linked recessive disorder affecting 1 in 5000
male births.[1]Mutations in theDMD gene result in the absence of the sarcolemmal protein
dystrophin, which leads to progressive muscle damage and fat replacement. Clinically, DMD
patients becomewheel chair bound by their mid-teens and die prematurely of cardiac/respira-
tory failure.[2, 3]
Glucocorticoid therapy is currently the only pharmacological intervention proven to delay
disease progression in muscles,[4, 5] however a number of promising novel experimental ther-
apies are at different clinical trials stages, e.g. antisense oligomer (AO) mediated exon skipping,
which aims to restore semi-functional protein products; and drugs to induce read-through
nonsense mutations.[6–8] Primary outcome measure in clinical trials currently rely on invasive
endpoints such as muscle biopsy to describe restoration of dystrophin in muscle fibres, provid-
ing only limited sampling of the pathology, or functional tests with restricted applicability and
variable reproducibility. For instance, the 6-minute-walk test (6-MWT) has been utilized as a
primary outcome end-point in phase II-III clinical trials;[8–10] however limitations of this
functional test include that it is motivation dependent[11] and can only be used for ambulant
boys. In addition, invasive endpoints such as muscle biopsy to assess restoration of dystrophin
in muscle fibres is often used as a pharmacodynamicsmarker, providing however only limited
information due to sampling limitation. Thus non-invasive and objective trial outcome mea-
sures applicable in ambulant and non-ambulant subjects are urgently required. Recent studies
have shown that magnetic resonance imaging (MRI) and spectroscopy (MRS) provide sensitive
markers of muscle pathology and disease progression in the lower limbs of DMD subjects, [12–
14], suggestingMRI-quantifiedmuscle fat content as a promising candidate biomarker. How-
ever, to date limited information is available regarding the potential of these methods to assess
upper limb disease progression, although initial data are encouraging:Wary et al. recently
reported forearmMRImeasurements in non-ambulant boys with DMD, observing a signifi-
cant correlation between forearm fat infiltration and time non-ambulant.[15]
The aim of our longitudinal study was to examine the ability of MRI muscle-fat measure-
ment to quantify disease progression in the upper limbs of non-ambulant DMD boys, and to
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compare the changes over 3, 6 and 12 months of MRI fat measurement compared with muscle
strength and validated functional assessments.
Methods
Participants
We recruited 15 non-ambulant DMD boys with a mean age of 13.3 y, (range: 10.8–17.3y.)
mean duration of non-ambulation 20.2 months (range: 4.7–41.6 months) and mean BMI 26.5
(range: 20.8–41.7). Assessments were performed at baseline, 3, 6 and 12 months; 6 subjects
withdrew from the study due to the frequent hospital visits, which were challenging to sustain
in the absence of therapeutic intervention.
At the time of the study all but one subject were receiving glucocorticoids.Ten age and gen-
der-matched healthy control subjects were scanned once (mean age: 14.6y, range: 13–17y;
mean BMI 21.5, range: 16.5–25.4). To assess measurement reproducibility 4 healthy controls
were re-tested at 6 weeks.
Written informed consent was obtained from the parents or guardians on behalf of the
minors/children enrolled in this study. The Brighton & Sussex Research National Ethics Com-
mittee approved the consent procedure and this study, which was performed in compliance
with the Declaration of Helsinki.
MRI acquisition and data analysis
Unilateral upper-limb MRI was performed at 3T (Siemens Skyra; Siemens, Erlangen, Ger-
many) using a flexible surfacematrix coil (4-Channel Flex Coil) wrapped around the dominant
forearm. Subjects lay in the scanner in the head-first supine position, with the dominant arm
to be imaged lying in a comfortable position on the scanner bed alongside the torso. Three-
point-Dixon[16] images were acquired (2D gradient-echo TE1/TE2/TE3/TR= 3.45/4.60/5.75/
102ms, flip angle 10°, nine 6mm axial slices, slice gap 12mm, FOV 18x18cm, matrix 320×320,
pixel size 0.56×0.56mm,NEX = 4).
Images were post-processed offline with a Python programming language pipeline accord-
ing to Glover and Schneider’s algorithm[17] assuming a single-peak fat component, and sepa-
rated fat (f) and water (w) images were used to calculate pixel-wise fat fraction (f.f.) maps
according to f :f : ¼ fwþf  100%.
Observers blinded to diagnosis manually defined individual muscle-group regions of inter-
est (ROI) on the TE = 3.45ms Dixon image to encompass each muscle-group boundary to the
fascia using the ITK Snap software.[18] For consistency all ROI definitions were subsequently
reviewed by a single blinded observer (MRBE). For each subject 3 of the 9 available baseline
image slices were chosen for analysis: a central slice defined as the first axial slice distal to the
supinator muscle, and proximal and distant slices centred ±74mm relative to the central slice.
For consecutive longitudinal data from the same subject, the slices selected for analysis were
carefully matched to the baseline slices by visual inspection and reference to a coronal scout
image. On each slice 10 forearmmuscle-group ROIs were defined (Fig 1).
Muscle ROIs on follow-up scans were defined in each case with reference to the respective
baselinemuscle segmentation for that subject to maintain longitudinal anatomical consistency.
The segmented ROI were transferred to the intrinsically co-registered f.f. maps, and visually
inspected for placement errors or the presence of gross artefact, and adjusted if necessary. For
all individual ROIs, custom-written software extracted individual muscle-group ROI mean f.f.
and muscle compartment cross-sectional area (CSA) in mm2. For each subject, at each of the
distal, central and proximal slice levels the following summarymeasures were determined:
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total muscle compartment f.f., calculated as the weighted-mean of the individual muscle-group
mean f.f.s, each ROI f.f. weighted by its respective CSA; total muscle compartment cross-sec-
tional area calculated as the sum of the individualmuscle CSAs, and remaining muscle area cal-
culated as:
cross   sectional muscle compartment area 
100   total muscle compartment f :f :
100
:
Functional assessment
In a clinical trial compatible mode, each subject was assessed as follows: 1) performance of
upper limb (PUL) module, a validated 74 point functional scale for motor performance relating
to everyday life activity;[19, 20]; 2) muscle strength for shoulder flexion, elbow extension and
flexion, and wrist extension measured in lbs using a hand-held myometer (Microfet, Hoggan,
UT); 3) MyoSet (Myopinch, Myogrip and Moviplate), a suite of recently validated novel tools
to assess strength and fatigability of the upper limb;[21, 22]; 4) Egen Klassification (EK2) inter-
view version 2, which is used to determine performance of tasks in daily life (total score = 51)
[23]; 5) spirometry and peak cough flow using a Vitalograph Pneumotrac 6800; and 6) record
of time to loss of ambulation (LOA) in months.
Statistical methods
BaselineMRI measures were compared between the DMD and healthy control groups using
unpaired t-tests. In the DMD group, changes in clinical measurements and MRI scores were
compared within boys over the 3 follow-up time points using mixedmodel regression analysis.
This method is suitable for unbalanced data, obtained as a result of loss to follow-up and
incomplete dataset, therefore accounting for different number of subjects at different time
points and differing betweenMRI and physiotherapy assessment. Furthermore, a separate
model was fitted for each outcome measurement with adjustment for length of time non-
Fig 1. Muscle segmentation (A) and raw 3-point Dixon (B) of the central slice in the dominant forearm of a healthy control.
DORSAL compartment: Extensor carpi ulnaris (ECU), extensor digiti minimi (EDM), extensor digitorum (ED), extensor pollicis longus
(EPL), abductor pollicis longus (APL), extensor carpi radialis longus/brevis and brachioradialis (ECRLB Br). VOLAR compartment:
flexor digitorum profundus and flexor pollicis longus (FDP), flexor digitorum superficialis and palmaris longus (FDS), flexor carpi ulnaris
(FCU), flexor carpi radialis (FCR).
doi:10.1371/journal.pone.0162542.g001
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ambulant; results are presented as adjusted mean changes for the 3 month, 6 month and 12
month periods, with 95% confidence intervals (CI). The data for each measure were assessed
for normality using the Shapiro-Francia W dash test and, where there was some evidence of
non-normality, we investigated the use of appropriate transformations. Findings were found to
be very similar for the transformed data and we therefore present results for untransformed
data only. To account for multiplicity a P-value <0.01 was considered significant.
Results
From the 15 subjects initially recruited, combinedMRI and clinical assessment data were
obtained for 9/15 subjects (mean age 13.2y; range: 11.1–17.6) at the 3 month follow-up and 7/
15 at both 6 the month (mean age 13.9y; range: 11.6–17.9) and 12-month (mean age 14.2y;
range: 11.8–18.2) time points. AlthoughMRI was overall well tolerated, 6 subjects found the
commitment to the study too demanding and withdrew before completing the full 12-month
assessments. In addition, MRI from 4 patients at 6 and 2 patients at 12 months were excluded
from the analysis due to subject-motion related image artefacts. Finally, MyoSet data could not
be collected for 4 subjects at 3 months, 2 subjects at 6 months and 1 subject at 12 months
because the tools were sent back to the manufacturer for yearly calibration or used in another
protocol. One patient contributed to baseline evaluation only.
Muscle MRI- fat transformation, cross-sectional area, and remaining
non-fat area
The central slice overall mean total muscle compartment f.f. in the DMD subjects was signifi-
cantly higher than for healthy controls (14.1%, 95% CI 8.4, 19.9 in DMD; 0.9%, 95% CI 0.7, 1.0
in healthy controls; p<0.001), as were individual muscle-group mean f.f. (Table 1 and Table A
in S1 Table). The central slice mean total cross-sectionalmuscle compartment area was
reduced in DMD (1702 mm2, 95% CI 1520, 1883 mm2) relative to the healthy controls (2389
mm2, 95% CI 1878, 2899 mm2; p = 0.006).
Table 1. Baseline characteristics of DMD subjects.
Mean 95% CI
CENTRAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 14.1 8.4; 19.9
PROXIMAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 17.5 10.9; 24.1
DISTAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 19.7 12.5; 26.9
CENTRAL SLICE DORSAL COMPARTMENT FAT FRACTION (%) 14.1 8.7; 19.5
CENTRAL SLICE VOLAR COMPARTMENT FAT FRACTION (%) 14.2 7.1; 21.3
ECRLB Br FAT FRACTION (%) 31.2 20.5; 41.8
CENTRAL SLICE TOTAL MUSCLE COMPARTMENT CROSS-SECTIONAL
MUSCLE AREA (mm2)
1702 1520;
1883
CENTRAL SLICE TOTAL REMAINING (NON-FAT) MUSCLE AREA (mm2) 1472 1254;
1690
MYOPINCH (Kg) 2.5 2.1; 2.9
MYOGRIP (Kg) 6.7 5.6; 7.8
PERFORMANCE OF UPPER LIMB (Total score = 74) 65.9 61.6; 70.3
PERFORMANCE OF UPPER LIMB (Shoulder domain score = 16) 9.9 6.8; 12.9
MOVIPLATE (taps in 30 seconds) 56.3 49.7; 62.9
Baseline means and 96% CI for the 15 DMD subjects
doi:10.1371/journal.pone.0162542.t001
Upper Limb Imaging and Functional Evaluation in Non-Ambulant DMD
PLOS ONE | DOI:10.1371/journal.pone.0162542 September 20, 2016 5 / 15
The extensor carpi radialis longus/brevis and the brachioradialis (ECRLB Br) group showed
the greatest f.f. difference betweenDMD and the healthy controls (Table A in S1 Table), with
an overall mean f.f. 31.2% (95% CI 20.5, 41.8%) in the DMD group vs healthy controls, which
was 1.8% (95% CI 0.7, 2.8%).
Longitudinally in the DMD group we observed a significant increase in central slice total
muscle compartment f.f. of 3.9% units mean change (95% CI 1.9, 5.7%) above baseline at 6
months (p<0.001, n = 7). At 12 months, the mean increase was 5.0% units (95% CI 3.2, 6.9)
above baseline (also n = 7) (Table 2, Figs 2 and 3a). Proximal and distal slice mean increases
were also significant at 12 months: 6.9% (95%CI 5.2, 8.7%; p<0.001) and 4.3% (95%CI 2.0,
6.6%; p<0.001) respectively (Table 2, Fig 3b and 3c). At 12 months, the dorsal compartment
was more affected than the volar compartment, with, at the central-slice level, a mean increase
of 6.3% units (95% CI 3.6, 9.1; p<0.001) compared to the volar compartment (3.4%, 95% CI
0.9, 5.7; p<0.01) (Table 2). All individual muscle groups showed significant f.f. increase over
one year (all p<0.001, Table B in S1 Table), with the ECRLB Br again being the most affected
muscle group, with a mean f.f. increase of 7.0% (95% CI 4.1, 10.0; p<0.001) (Table 2).
Mean central slice total cross-sectionalmuscle area in the DMD subjects increased above
baseline by 140 mm2 (95% CI 50.9, 229.1 mm2) at 12 months (p<0.01), although the total
remaining (i.e. non-fat) muscle area, which at baseline was 1472 mm2 (95% CI 1254, 1690
mm2), did not show significant change (mean change 22 mm2, 95% CI -48, 92 mm2, p = 0.5).
Excluding the DMD boy who was not receiving steroids from the analysis did not change
our statistical conclusions (S2 Table). In healthy controls, the central slice overall mean muscle
f.f. change between baseline and 6 weeks was 0.2 (95%CI (-0.2, 0.5 p = 0.26, n = 4). Individual
subject differences are reported in Table C in S1 Table.
Clinical assessment
Functional and strength mean values at baseline are reported in Table 1.
In 9 DMD subjects, meanMyoPinch measured pinch strength decreased significantly from
baseline by 0.38 kg (95% CI -0.53, -0.22; p<0.01, n = 9) at 6 months (Table 2, Fig 3e), and grip
strength measured by MyoGrip had decreased significantly by 1.0 kg (95% CI -1.56, -0.51;
p<0.001, n = 8) at 12 months from baseline. The PUL total score and shoulder domain index
had both deteriorated significantly at 12 months, with group mean decreases of 9.2 (95% CI
-11.9; -6.4; p<0.001) and –6.9 (95% CI -9.0; -4.9; p<0.001) respectively in 9 DMD subjects.
Distal arm functional assessment using the MoviPlate detected a significant improvement of
function at 6 months (4.69, 95% CI 2.0, 7.4; p = 0.001, n = 9) with subsequent decline (Table 2,
Fig 3g). These conclusions remained unchanged on excluding the subject not treated with ste-
roids (S2 Table). All other evaluations, including spirometry and muscle strength measurement
with myometry, failed to reach statistical significance in our cohort. Detailed results are
reported in the appendix (S3 Table and S1 Fig).
Discussion
Our study suggests that upper limb forearmMRI fat quantification is a sensitive biomarker for
disease progression in non-ambulant DMD boys. Not only couldMRI discriminate DMD
from healthy controls (p = 0.002), but longitudinally, group-wise increased forearmmuscle-fat
infiltration in the dominant forearm of DMD subjects was significant (p< 0.001) as early as 6
months from baseline. At one year, the DMD group mean central slice muscle f.f. increase was
5.0% (95% CI 3.2, 6.9%) above a baseline value of 14.1% (95% CI 8.4, 19.9%; p<0.001). In addi-
tion, we demonstrated that whilst in the patient group mean total muscle compartment cross-
sectional area increased over 12 months, the remaining total non-fat muscle area within the
Upper Limb Imaging and Functional Evaluation in Non-Ambulant DMD
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Table 2. MRI and clinical indices mean changes (95% CI) from baseline from analysis of variance.
3 months 6 months 12 months
CENTRAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%)
Mean change from baseline (95% CI) 1.4 3.9 5.0
(-0.3, 3.2) (1.9, 5.7) (3.2, 6.9)
No. of subjects 9 7 7
P value 0.11 < 0.001 < 0.001
PROXIMAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%)
Mean change from baseline (95% CI) 2.1 4.5 6.9
(0.5, 3.7) (2.7, 6.3) (5.2, 8.7)
No. of subjects 9 7 7
P value 0.01 < 0.001 < 0.001
DISTAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%)
Mean change from baseline (95% CI) 2.2 2.2 4.3
(0.06, 4.3) (-0.05, 4.5) (2.0, 6.6)
No. of subjects 9 7 7
P value 0.04 0.06 < 0.001
CENTRAL SLICE DORSAL COMPARTMENT FAT FRACTION (%)
Mean change from baseline (95% CI) 1.7 5.5 6.3
(-0.9, 4.4) (2.7, 8.3) (3.6, 9.1)
No. of subjects 9 7 8
P value 0.20 <0.001 <0.001
CENTRAL SLICE VOLAR COMPARTMENT FAT FRACTION (%)
Mean change from baseline (95% CI) 1.3 0.7 3.4
(-1.0, 3.7) (-1.8, 3.3) (0.9, 5.7)
No. of subjects 9 7 8
P value 0.27 0.58 <0.01
ECRLB Br FAT FRACTION (%)
Mean change from baseline (95% CI) 1.7 6.1 7.0
(-1.1, 4.5) (3.1, 9.2) (4.1, 10.0)
No. of subjects 9 7 8
P value 0.24 <0.001 <0.001
CENTRAL SLICE TOTAL MUSCLE COMPARTMENT CROSS-SECTIONAL MUSCLE AREA (mm2)
Mean change from baseline (95% CI) -5.4 42.1 140
(-88.1, 77.4) (-47.0, 131.2) (50.9, 229.1)
No. of subjects 9 7 7
P value 0.90 0.36 < 0.01
CENTRAL SLICE TOTAL REMAINING (NON-FAT) MUSCLE AREA (mm2)
Mean change from baseline (95% CI) -28.4 -32.1 22.0
(-93.6, 36.8) (-102.6, 38.1) (-48.2, 92.3)
No. of subjects 9 7 7
P value 0.39 0.37 0.54
MYOPINCH (Kg)
Mean change from baseline (95% CI) -0.1 -0.38 -0.50
(-0.27, 0.03) (-0.53, -0.22) (-0.66, -0.34)
No. of subjects 10 9 8
P value 0.12 < 0.001 < 0.001
MYOGRIP (Kg)
Mean change from baseline (95% CI) -0.22 -0.50 -1.04
(-0.70, 0.27) (-1.01, 0.002) (-1.56, -0.51)
(Continued )
Upper Limb Imaging and Functional Evaluation in Non-Ambulant DMD
PLOS ONE | DOI:10.1371/journal.pone.0162542 September 20, 2016 7 / 15
Table 2. (Continued)
3 months 6 months 12 months
No. of subjects 10 9 8
P value 0.38 0.05 < 0.001
PERFORMANCE OF UPPER LIMB (Total score = 74)
Mean change from baseline (95% CI) -0.5 -2.6 -9.2
(-2.8, 1.9) (-5.2, -0.03) (-11.9, -6.4)
No. of subjects 14 11 9
P value 0.69 0.05 < 0.001
PERFORMANCE OF UPPER LIMB (Shoulder domain score = 16)
Mean change from baseline (95% CI) -0.7 -1.0 -6.9
(-2.6, 1.1) (-2.9, 0.9) (-9.0, -4.9)
No. of subjects 14 11 9
P value 0.42 0.32 < 0.001
MOVIPLATE (taps in 30 seconds)
Mean change from baseline (95% CI) 2.3 4.7 1.7
(-0.02, 4.6) (2.01, 7.4) (-0.8, 4.3)
No. of subjects 11 9 8
P value 0.05 0.001 0.19
P value < 0.01 was considered significant. ECRLB Br = extensor carpi radialis longus/brevis and
brachioradialis
doi:10.1371/journal.pone.0162542.t002
Fig 2. 3-point Dixon fat-fraction (f.f.) maps of dominant forearm central slice at baseline (left images)
and 12 months (right images). Top: 13 y.o. DMD, non-ambulant for 40 months, and on daily steroids.
Overall mean f.f. at baseline = 7.6% (A) and 12 months = 9.7% (B). Bottom: 11 y.o. DMD, non-ambulant for
14 months, not on steroid therapy. Mean f.f. at baseline = 30.7% (C) and 12 months = 43.3% (D). (Grey-level
bars represent f.f. from 0 to 100%).
doi:10.1371/journal.pone.0162542.g002
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muscle compartments did not change. We speculate that this apparent overall increase in vol-
ume of the muscle in part reflects the process of fat infiltration or tissue transformation in
DMD, although it remains to be established to what extent muscle pseudo-hypertrophy in
DMD is attributable to this cause. All muscle groups showed a significant f.f. increase over one
year (all p<0.001), with the dorsal compartment more affected than the volar. The ECRLB Br
was the most severely affected individual muscle group at baseline (mean f.f. 31.2, 95% CI 20.5;
41.8%) with the most marked f.f. increase over 12 months equal to 7.0% (95% CI 4.1, 10.0;
p<0.001). The muscle fat transformation extended over the whole length of the lower arm:
proximal and distal slices showed a similar progression of fat transformation, although the
proximal slice was more severely affected, both across the total muscle cross-section, and
within individual muscles.
Fig 3. Plots of individual trajectories for (A) central slice overall muscle %fat fraction, (B) proximal
slice overall muscle %fat fraction, (C) distal slice overall muscle %fat fraction, (D) MyoPinch, (E) total
score for Performance of Upper limb, (F) PUL Shoulder domain score, (G) MoviPlate and (H)
MyoGrip. f.f. = fat fraction. PUL = Performance of upper limb.
doi:10.1371/journal.pone.0162542.g003
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Regarding the clinical evaluations, at 6 months we observed a significant decrease from
baseline in MyoPinch-measured pinch strength of 0.38 kg (95% CI -0.53, -0.22, p<0.001). This
was sustained at one year (-0.50 kg 95% CI –0.66, -0.34 kg from baseline, p<0.001). Over 12
months handgrip strength also significantly reduced by 1.0 kg (95% CI -1.56, -0.51 p<0.001).
In line with previous publications, [21, 22] the MoviPlate, a tapping device designed to measure
endurance of upper limb, showed a modest improvement over 6 months followed by a decline.
This phenomenon has been observed in the early non-ambulant DMD phases (i.e. boys who
are wheelchair-bound< 3years) [21] and may be explained by a distal upper limb functional
training effect or by a motor strategy improvement following loss of ambulation with increased
demands on arm function. The PUL scale showed highly significant loss of function at 12
months (p<0.001), with a mean drop in score of 9.2 (95% CI -11.9; -6.4) out of 74; this numeri-
cal result was predominantly driven by the loss of function in the shoulder domain. Interest-
ingly, loss of shoulder-girdle muscle function in our study was associated with progressive
lower armmuscle fat transformation, suggesting our observed changes reflect pathology not
limited to the forearmmuscles. Although specificmuscle group related strength was measured,
including shoulder extension, elbow flexion and extension, and wrist extension, these assess-
ments did not yield any significant results within the study time frame in this relatively small
patient cohort. None of the other assessments, including spirometry and a patients’ reported
questionnaire changed significantly over 12 months.
When designing clinical trials for rare disorders, critical issues which need to be taken into
account include: selecting an endpoint which is as observer and subject-motivation indepen-
dent as possible; reducing the burden of clinical-trial participation, favouring non-invasive
endpoints; and selecting an endpoint capable of identifying clinically meaningful changes in a
small cohort of patients. MRI is being increasingly applied to neuromuscular disorders, not
only for defining phenotype [24, 25], but also to provide biomarkers responsive to therapies.
[26, 27] Studies have already demonstrated the suitability of MRI to characterise pathology in
DMD, [12, 28] monitoring disease progression in the lower limbs [13, 14, 29] and in the upper
limb of non-ambulant subjects. [15] Further studies have explored imaging in combination
with lower extremity strength and/or functional assessment. [30–35] A recent study has shown
that lower limbMRI and MRS can effectively detect the beneficial effect of glucocorticoid ther-
apy both in cross-sectional comparison and at 3 months.[27] In relation to upper limb muscle
MRI, to date, only one cross-sectional study reported on forearm fat transformation in 24 non-
ambulant DMD subjects with deletions amenable to exon 53 skipping therapy, and showed a
strong positive correlation betweenmuscle fat content and disease severity expressed as time
non-ambulant. [15]
Overall,MRI combines the advantages of being non-invasive and repeatable longitudinally,
allowing investigators to have a deep understanding of the timing and the extent of muscle
response to therapeutic intervention, in multiple muscle groups. This is in contrast to muscle
biopsies, which are not only invasive procedure, but also limited to a small sample in a single
muscle. There is also potential to combine multi-centre MRI data in multi-centre trials: inter-
national expert workshops under the auspices of the TREAT-NMD have proposed harmonized
protocols for skeletal muscle MRI-based outcome measures in this context,[36] and a multi-
centre study evaluated the reproducibility among centres of MRI and MRS in lower limbs of
DMD boys.[37] Of the available MRI readouts, a number of studies support the notion that the
3-point-Dixon technique [16, 38] may be the best currently available method to measure fat
transformation in DMD associated with disease progression in DMD.[31, 36, 39] Indeed,
lower-limb MRI and MRS have been included as exploratory endpoints in clinical trials for
ambulant boys in patients treated with Drisapersen [24] and in the on-going EU FP7 funded
SKIP-NMD programme, which aims to restore dystrophin with morpholino antisense
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oligomer exon skipping for patients with deletions skippable by exon 53, and which will yield
results by 2016.[26, 40]
The current study, provides longitudinal MRI natural history data regarding fat transforma-
tion in the forearm of non-ambulant DMD, with corroborative detailed clinical evaluation:
bothMRI and Myopinch sensitively detected changes at 6 months and therefore both qualify
as complementary outcome measures. MRI allows highly specific assessment of individual
muscles within in a single examination while probing simultaneously across the different mus-
cle groups at multiple levels, whereas Myopinch measures a specific function of strength
reflecting the combined effort of one distinct muscle group.
Importantly, comparing our MRI measurements with the functional data supports the
validity of MRI-determined forearm f.f. as a clinically-relevant marker of disease progression
in DMD. The progressive fat transformation measured by MRI in our cohort may be associated
not only with a decline in strength (for pinching at 6 months, and gripping at 12 months), but
also in functional impairment as measured by the PUL at 1 year; we therefore conclude that f.f.
increase is a clinically meaningful index of pathology.
The high responsiveness of f.f. to pathological change in DMD with the ability to detect sig-
nificant change at as early as 6 months in a small cohort of patients, should allow adequately
powered clinical trials with shorter duration, and or with reduced sample size requirements
than those based upon conventional clinical end-points alone. For example, in our study we
observed total cross-sectionalmuscle f.f. change at 6 months from baseline of approximately
4% (± 3%) in 7 DMD subjects. In a hypothetical treatment trial, if this change was compared
with an expectedmean change (treatment effect size) of 0.5% in a treatment arm,[27] and
assuming a similar SD, a power of 90% and significance level of 5%, a minimum of 16 patients
per group would be required. This would considerably reduce trial sample size and duration
compared to studies using, for example, the 6-MWT as a clinical end-point. Furthermore, our
data also supports the feasibility of extending eligibility for DMD treatment trial inclusion to
non-ambulant as well as ambulant, since disease progression, and therefore we may assume
treatment response, can be quantified by MRI in the upper limb.
Our study protocol was well tolerated overall, allowing adequate rest between the image
acquisition and physiotherapy assessment. The 6 subjects who withdrew from the study
reported that the frequent hospital visits (i.e. 4 in 12 months) were difficult to sustain in
absence of therapeutic intervention. Cooperation in lying still is essential for MRI, and indeed
4 of our subjects moved during imaging necessitating exclusion of those data. Reducing the
overall MRI examination time by excluding non-essential acquisition sequences or exploiting
MRI acceleration strategies [41] may improve patient compliance and reduce the study bur-
den in future studies. However, MRI results are nevertheless likely far less subject motivation-
dependent than conventional primary endpoints such as the 6-MWT used in ambulant clini-
cal trials, in which performancemay be affected by the level of tiredness or motivation on the
day.
Limitations of our study include the relatively small sample size, exacerbated by the number
of subjects who withdrew from the study, with inclusion restricted to a selected patient popula-
tion (i.e. non-ambulant and below 18 years of age). It is likely that the measures we investigated
may well vary according to age at baseline and length of time non ambulant, and it would be of
interest to adjust for these factors in a future larger study. Although it was not our objective to
explore the effect of treatment including steroids on MRI response, this may be important;
excluding data from the single patient not on steroid therapy from our analysis did not alter
our findings. Finally, our MRI coverage was in this study limited to the dominant forearm, and
the f.f. analysis to three slices; future studies will address pathology and disease progression in
limb regions and muscle groups not included in this work.
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In conclusion, our study provides novel data to inform rational imaging endpoint specifica-
tion and trial design for studies in non-ambulant Duchenne cohorts. Although our cohort of
boys was relatively small, we were able to document objective changes in MRI measures of
muscle fat transformation and validate their clinical relevance by demonstrating a strong asso-
ciation with measures of muscle force, function and disease progression. The time course of the
measures’ response to deterioration suggests detection of disease stabilization or improvement
over periods as short as 6–12 months is readily achievable in small cohorts. The complemen-
tarity of the methods suggests a mechanistic relationship betweenmuscle tissue fat transforma-
tion, muscle force production and overall function.
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